Compare Abeona Therapeutics Inc (ABEO) vs Okta, Inc. (OKTA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Okta, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Okta, Inc. trades at $147 (market cap $25.81B). The key difference: Okta, Inc. is far larger — about 69.1× Abeona Therapeutics Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, Abeona Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | OKTA | |
|---|---|---|
Market Cap | $373.32M | $25.81B |
Sector | Health | Technology |
52-Week High | $7.23 | $148.60 |
52-Week Low | $4.17 | $62.93 |
Enterprise Value | $228.22M | $23.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
OKTA trades at $148.47, up 4.99% on the day, with strong technical momentum and bullish moving averages. The company reported revenue of $2.61B in 2025, achieving profitability with net income of $28M after years of losses. Recent earnings beats and AI-driven demand have fueled investor optimism, though valuation multiples remain elevated.
Outlook is positive with robust revenue growth and improving margins, but high P/E of 107.68 poses valuation risk. Analyst consensus is bullish with 72.55% buy ratings, though price target of $121.08 suggests caution near current levels. Key risks include competition and execution on AI monetization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
